KBC Group
ZNTL icon

KBC Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

KBC Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-904
Closed -$18K – 1911
2023
Q3 		$18K Buy
+904
New +$22.9K ﹤0.01% 1894

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

KBC Group's ZNTL Position: Q4 2023 in Review

KBC Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 904 shares — an estimated $18K sold.

KBC Group first reported a position in ZNTL in Q3 2023 and held it in 1 quarter. The position peaked at $18K in Q3 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • KBC Group reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • KBC Group sold 904 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $18K.
  • KBC Group first reported a position in Zentalis Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • KBC Group's Zentalis Pharmaceuticals position peaked at $18K in Q3 2023.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on KBC Group's 13F filing for Q4 2023, filed 13 Feb 2024.